Skip to main content

MPS IV A

0
Pipeline Programs
1
Companies
4
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

BioMarin Pharmaceutical
4 programs
A Clinical Assessment Study of Subjects With Mucopolysaccharidosis IVA (Morquio Syndrome)N/A1 trial
BMN 110PHASE_1_21 trial
BMN 110PHASE_1_21 trial
BMN 110 WeeklyPHASE_31 trial
Active Trials
NCT00787995Terminated353Est. Jul 2014
NCT01242111Terminated20Est. Jul 2014
NCT00884949Completed20Est. Mar 2011
+1 more trials

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
BioMarin PharmaceuticalBMN 110 Weekly
BioMarin PharmaceuticalBMN 110
BioMarin PharmaceuticalBMN 110
BioMarin PharmaceuticalA Clinical Assessment Study of Subjects With Mucopolysaccharidosis IVA (Morquio Syndrome)

Clinical Trials (4)

Total enrollment: 570 patients across 4 trials

A Double-Blind Study to Evaluate the Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)

Start: Feb 2011Est. completion: Aug 2012177 patients
Phase 3Completed

A Study to Evaluate the Long-Term Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)

Start: Nov 2010Est. completion: Jul 201420 patients
Phase 1/2Terminated

A Study to Evaluate the Safety, Tolerability and Efficacy of BMN 110 in Subjects With Mucopolysaccharidosis IVA

Start: Apr 2009Est. completion: Mar 201120 patients
Phase 1/2Completed
NCT00787995BioMarin PharmaceuticalA Clinical Assessment Study of Subjects With Mucopolysaccharidosis IVA (Morquio Syndrome)

A Clinical Assessment Study of Subjects With Mucopolysaccharidosis IVA (Morquio Syndrome)

Start: Oct 2008Est. completion: Jul 2014353 patients
N/ATerminated

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.